AU2016347471B2 - Methods of treatment using anti-IL-17A/F antibodies - Google Patents

Methods of treatment using anti-IL-17A/F antibodies Download PDF

Info

Publication number
AU2016347471B2
AU2016347471B2 AU2016347471A AU2016347471A AU2016347471B2 AU 2016347471 B2 AU2016347471 B2 AU 2016347471B2 AU 2016347471 A AU2016347471 A AU 2016347471A AU 2016347471 A AU2016347471 A AU 2016347471A AU 2016347471 B2 AU2016347471 B2 AU 2016347471B2
Authority
AU
Australia
Prior art keywords
antibody
human
gly
thr
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016347471A
Other languages
English (en)
Other versions
AU2016347471A1 (en
Inventor
Sophie GLATT
Lucian IONESCU
Margaret Jones
Ruth Oliver
Stevan Graham Shaw
Foteini STRIMENOPOULOU
Venkata Pavan Kumar VAJJAH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57223670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016347471(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AU2016347471A1 publication Critical patent/AU2016347471A1/en
Application granted granted Critical
Publication of AU2016347471B2 publication Critical patent/AU2016347471B2/en
Assigned to UCB Biopharma SRL reassignment UCB Biopharma SRL Amend patent request/document other than specification (104) Assignors: UCB BIOPHARMA SPRL
Priority to AU2023255037A priority Critical patent/AU2023255037A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016347471A 2015-10-27 2016-10-26 Methods of treatment using anti-IL-17A/F antibodies Active AU2016347471B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023255037A AU2023255037A1 (en) 2015-10-27 2023-10-27 Methods of treatment using anti-IL-17A/F antibodies

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562246989P 2015-10-27 2015-10-27
US62/246,989 2015-10-27
US201662303230P 2016-03-03 2016-03-03
US62/303,230 2016-03-03
US201662346826P 2016-06-07 2016-06-07
US62/346,826 2016-06-07
US201662405546P 2016-10-07 2016-10-07
US62/405,546 2016-10-07
PCT/EP2016/075821 WO2017072183A1 (en) 2015-10-27 2016-10-26 Methods of treatment using anti-il-17a/f antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023255037A Division AU2023255037A1 (en) 2015-10-27 2023-10-27 Methods of treatment using anti-IL-17A/F antibodies

Publications (2)

Publication Number Publication Date
AU2016347471A1 AU2016347471A1 (en) 2018-05-10
AU2016347471B2 true AU2016347471B2 (en) 2023-08-03

Family

ID=57223670

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016347471A Active AU2016347471B2 (en) 2015-10-27 2016-10-26 Methods of treatment using anti-IL-17A/F antibodies
AU2023255037A Pending AU2023255037A1 (en) 2015-10-27 2023-10-27 Methods of treatment using anti-IL-17A/F antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023255037A Pending AU2023255037A1 (en) 2015-10-27 2023-10-27 Methods of treatment using anti-IL-17A/F antibodies

Country Status (16)

Country Link
US (3) US11492396B2 (enExample)
EP (1) EP3368570A1 (enExample)
JP (5) JP6931648B2 (enExample)
KR (2) KR20180067676A (enExample)
CN (2) CN116059350A (enExample)
AU (2) AU2016347471B2 (enExample)
BR (1) BR112018008075A2 (enExample)
CA (1) CA3001260A1 (enExample)
CL (3) CL2018001135A1 (enExample)
CO (1) CO2018004493A2 (enExample)
IL (1) IL258515A (enExample)
MX (4) MX2018005031A (enExample)
MY (3) MY196489A (enExample)
RU (1) RU2754683C2 (enExample)
SG (2) SG10202112586WA (enExample)
WO (1) WO2017072183A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
EP4143342A1 (en) * 2020-04-30 2023-03-08 Janssen Pharmaceutica NV Methods of identifying modulators of the il-17 pathway
EP4289863A4 (en) * 2020-12-17 2025-04-09 Shanghai Huaota Biopharmaceutical Co., Ltd. BISPECIFIC ANTIBODY AGAINST IL-17A AND IL-36R AND USE THEREOF
EP4471427A1 (en) * 2023-05-31 2024-12-04 Centre Hospitalier Universitaire De Nice Biomarker for spondyloarthitis diagnostic and response to treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095662A1 (en) * 2011-01-14 2012-07-19 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ES2223040T3 (es) 1991-04-10 2005-02-16 The Scripps Research Institute Bibliotecas de receptor heterodimerilo que usan fagemidos.
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2347840T3 (es) 2006-02-10 2010-11-04 Zymogenetics, Inc. Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion.
AU2007226627B2 (en) * 2006-03-10 2012-09-20 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CN104628855A (zh) * 2008-05-05 2015-05-20 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
LT2334705T (lt) 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
RU2394575C1 (ru) * 2009-04-13 2010-07-20 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Способ лечения псориаза
PE20120815A1 (es) * 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
BR112013008501A2 (pt) 2010-10-08 2016-08-16 Novartis Ag métodos para o tratamento de psoríase usando anatgonistas de il-17
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN104011223A (zh) 2011-11-21 2014-08-27 诺华股份有限公司 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
BR112014025768A2 (pt) 2012-04-20 2017-07-04 Novartis Ag métodos de tratamento de espondilite anquilosante usando antagonistas de il-17
GB201213571D0 (en) 2012-07-31 2012-09-12 Univ Leuven Kath Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
SG11201505330QA (en) * 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
BR112017003332A2 (pt) 2014-09-10 2017-11-28 Novartis Ag uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
CN108367074A (zh) 2015-10-19 2018-08-03 诺华股份有限公司 使用白介素-17（il-17）拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
GB201522391D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095662A1 (en) * 2011-01-14 2012-07-19 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f

Also Published As

Publication number Publication date
JP2021130707A (ja) 2021-09-09
AU2016347471A1 (en) 2018-05-10
MY206805A (en) 2025-01-08
IL258515A (en) 2018-05-31
JP2025037926A (ja) 2025-03-18
CN108350068A (zh) 2018-07-31
US20230279093A1 (en) 2023-09-07
MX2023004315A (es) 2023-05-08
CA3001260A1 (en) 2017-05-04
CL2021002816A1 (es) 2022-07-29
MX2018005031A (es) 2018-06-13
US20230287100A1 (en) 2023-09-14
CL2018001135A1 (es) 2019-05-10
CO2018004493A2 (es) 2018-11-30
RU2018118029A3 (enExample) 2020-09-17
CL2021002815A1 (es) 2022-07-29
MX2022009379A (es) 2022-09-07
EP3368570A1 (en) 2018-09-05
JP6931750B2 (ja) 2021-09-08
JP2018535961A (ja) 2018-12-06
RU2018118029A (ru) 2019-12-04
WO2017072183A1 (en) 2017-05-04
KR20240156437A (ko) 2024-10-29
RU2754683C2 (ru) 2021-09-06
JP6931648B2 (ja) 2021-09-08
MX2022009380A (es) 2022-09-07
US11492396B2 (en) 2022-11-08
MY196489A (en) 2023-04-17
CN116059350A (zh) 2023-05-05
JP7176044B2 (ja) 2022-11-21
SG11201802887PA (en) 2018-05-30
MY207225A (en) 2025-02-06
JP2021119168A (ja) 2021-08-12
AU2023255037A1 (en) 2023-11-16
SG10202112586WA (en) 2021-12-30
JP2023025019A (ja) 2023-02-21
US20190292255A1 (en) 2019-09-26
KR20180067676A (ko) 2018-06-20
BR112018008075A2 (pt) 2018-12-04

Similar Documents

Publication Publication Date Title
DK2663577T3 (en) Antibody that binds to IL-17A and IL-17F
AU2016347471B2 (en) Methods of treatment using anti-IL-17A/F antibodies
ES2614636T3 (es) Moléculas de anticuerpos que se unen a IL-17 humana
RU2746926C2 (ru) Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких
KR101836217B1 (ko) Ｉｌ-１７ａ 길항제
TWI476004B (zh) 對人類ｉｌ－１３具結合專一性的抗體分子
US20130243772A1 (en) Antibody molecules having specificity for human ox40
TW201412774A (zh) 能結合胸腺基質淋巴細胞生成素之抗原結合蛋白
CN101861336A (zh) 人gm-csf抗原结合蛋白质
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
NZ613286B2 (en) Antibody molecules which bind il-17a and il-17f
HK1187929A (en) Antibody molecules which bind il-17a and il-17f
HK1187929B (en) Antibody molecules which bind il-17a and il-17f

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCB BIOPHARMA SRL

Free format text: FORMER NAME(S): UCB BIOPHARMA SPRL

FGA Letters patent sealed or granted (standard patent)